Complex Injectable Generics Pipeline
Various
ANDA Filed / DevelopmentIn Development
Key Facts
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a vertically integrated biopharmaceutical company with a core mission to develop and deliver high-quality, complex generic and proprietary injectable, inhalation, and intranasal medications. The company has established a strong commercial footprint with products like BAQSIMI®, the leading prescribed glucagon in the U.S., and has been recognized by the FDA for its efforts in alleviating critical drug shortages. Its strategic direction leverages proprietary technological platforms to advance a pipeline of biosimilars and innovative drug delivery systems, aiming to provide accessible treatments across therapeutic areas such as diabetes, respiratory diseases, and anemia.
View full company profileOther Various Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Programs | Richter Gedeon | Phase 3 |
| Oligonucleotide APIs | Bachem | Clinical/Commercial |
| Novel Plasma-derived Therapies | Tiantan Bio | Pre-clinical |
| Generic Portfolio | Strides Pharma | Approved |
| New Product Launches | FDC India | Development/Filing |
| Generic Products Portfolio | Celon Pharma | Approved/Commercial |
| New Generic Filings (e.g., for US/EU) | Bliss GVS Pharma | Regulatory Review |
| Pipeline of Complex Generics | Mayne Pharma Group | Development |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |